Dammarenediol II enhances etoposide‐induced apoptosis by targeting O ‐ GlcNAc transferase and Akt/ GSK3β / mTOR signaling in liver cancer
Open Access
- 30 December 2025
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 20 (6) , 1591-1611
Abstract
Combining chemotherapy with chemosensitizing agents is a common strategy to enhance anticancer efficacy while mitigating treatment‐related side effects. This study investigated the potential of dammarenediol II (DM2), a ginsenoside precursor, to enhance the anticancer effects of etoposide by downregulating O ‐linked β‐N‐acetylglucosamine modification ( O ‐GlcNAcylation) and modulating the Akt signaling pathway in HepG2 human liver cancer cells. The effect of DM2 on O ‐GlcNAcylation regulation was analyzed using Pharmaco‐Net, an artificial intelligence–driven drug screening platform and further validated using O ‐GlcNAc transferase (OGT) activity assay. DM2 cotreatment enhanced etoposide's anticancer efficacy, which was quantitatively evaluated by viability, Annexin V binding, membrane integrity, and caspase‐3/7 activity assays in HepG2 cells. Results showed that DM2 reduced O ‐GlcNAc levels by directly interacting with OGT, as confirmed through Pharmaco‐Net. Cotreatment with 40 μ m DM2 and 20 μ m etoposide produced synergistic anticancer effects, lowering etoposide's IC 50 for cell viability by 2.29‐fold and its EC 50 for caspase‐3/7 activity by 3.64‐fold. Mechanistically, DM2 dose‐dependently suppressed Akt/GSK3β/mTOR signaling. Using the Akt activator SC79, additional experiments confirmed that Akt signaling acts downstream of O ‐GlcNAcylation regulated by etoposide and DM2. These effects were also observed in multiple human liver cancer cell lines, as well as in A549 lung and Caco‐2 colorectal cancer cells. This supports the broader anticancer and Akt‐inhibitory potential of DM2. This study is the first to demonstrate that DM2 enhances anticancer synergy by suppressing O ‐GlcNAcylation and Akt signaling, highlighting its potential as a novel chemotherapy adjuvant.Keywords
Funding Information
- Korea Ginseng Corporation
This publication has 62 references indexed in Scilit:
- Downregulation of O‐GlcNAcylation enhances etoposide‐induced p53‐mediated apoptosis in HepG2 human liver cancer cellsFEBS Open Bio, 2025
- Primary mediastinal choriocarcinoma in a woman treated with VIP therapy instead of BEP therapy for the prevention of postoperative acute respiratory distress syndromeInternational Cancer Conference Journal, 2024
- Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- O‐GlcNAcylation: cellular physiology and therapeutic target for human diseasesMedcomm, 2023
- Dual regulation of fatty acid synthase (FASN) expression by O-GlcNAc transferase (OGT) and mTOR pathway in proliferating liver cancer cellsCellular and Molecular Life Sciences, 2021
- Cross regulation between mTOR signaling and O-GlcNAcylationJournal of Bioenergetics and Biomembranes, 2018
- Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatmentMedicinal Research Reviews, 2017
- Dammarenediol-II Prevents VEGF-Mediated Microvascular Permeability in Diabetic MicePhytotherapy Research, 2015
- Potential role of O‐GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitroBiotechnology and Applied Biochemistry, 2015
- O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantationMedical Oncology, 2011